Altre lingue HK inno.N Corporation

Azioni

A195940

KR7195940002

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 30/04/2024			Variaz. 5gg	Var. 1 gen.
38.750 ^KRW	-1,27%		+2,51%	-12,82%

2022	Sebela Pharmaceuticals® acquisisce i diritti di licenza esclusivi da HK inno.N Corporation per sviluppare e commercializzare Tegoprazan negli Stati Uniti e in Canada.	CI
2022	Sebela Pharmaceuticals entra in una partnership esclusiva con HK inno.N Corporation	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada	28/10/22
Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation	19/10/22
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.	09/08/22
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.	09/08/22
HK inno.N Corporation's Equity Buyback announced on February 9, 2022, has expired with 574,608 shares, representing 1.99% for KRW 24,180.98 million.	09/08/22
Indian Indices Close in the Red Midweek; Shree Cement Slides 4%	11/05/22
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.	11/05/22
Dr. Reddy's to Market HK inno.N's Gastrointestinal Diseases Drug in India, Emerging Markets	11/05/22
Dr. Reddy's Laboratories Ltd. Enters into an Exclusive Partnership with South Korea-Based HK Inno.N Corporation	11/05/22
HK inno.N's Gastroesophageal Reflux Disease Drug Gets Marketing Approval in China	18/04/22
Y-Biologics Inc. announced that it expects to receive KRW 30 billion in funding from a group of investors	24/02/22
HK inno.N Corporation announces an Equity Buyback for KRW 24,200 million worth of its shares.	09/02/22
HK inno.N Corporation authorizes a Buyback Plan.	09/02/22
Kolmar Korea to Acquire 40% Stake in Biotech Firm Next & Bio	30/12/21
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021	28/12/21
HK inno.N Enters License Agreement for Gastroesophageal Reflux Drug in the US	27/12/21
HK inno.N Corporation(KOSDAQ:A195940) added to S&P Global BMI Index	20/12/21
HK inno.N Corporation has completed an IPO in the amount of KRW 596.903 billion.	03/08/21
HK inno.N Corporation has filed an IPO.	04/05/21
HK inno.N Corporation announced that it has received KRW 49.9999765 billion in funding from Kolmar Korea Co., Ltd.	22/04/21

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue HK inno.N Corporation

Azioni

A195940

KR7195940002

Altre lingue

Filtri